UN 5th High Level Meeting on HIV/AIDS: Civil society says “Yes — AND” to the 2021 political declaration

Maureen Luba Milambe is the African Regional Advocacy Advisor: COMPASS and AVAC, based in Malawi. This piece first appeared on Science Speaks.

On Tuesday (June 8), the UN General Assembly voted overwhelmingly to approve the 2021 Political Declaration on HIV and AIDS introduced as part of the now fifth High Level Meeting on HIV/AIDS. Previous Declarations were accepted by unanimous consent, following months of negotiations. This year’s Political Declaration includes much to applaud, including new ambitious targets for prevention, investment goals to ensure everyone who needs treatment has access to it, and a financial and moral commitment to end gender inequality, stigma and discrimination. While all true, the overwhelming vote in favor, 165-5 (it was unexpectedly forced to a vote by the Russian Federation) obscures divisions that still exist around human rights and support for key populations and will undermine the targets and goals set forth in the declaration for the next five years, unless we pay heed.

The Russian Federation and a handful of other countries worked in the weeks ahead of the HLM to eliminate mention of harm reduction and rights-based programming, and weaken provisions related to key populations and youth. As Permanent Representative of Australia and meeting co-facilitator Mitchell Fifield noted, the Russian Federation made 73 changes to the document and then voted against the declaration it had weakened. Then after the vote, many countries that voted in favor of the declaration quickly disassociated themselves from the areas in it that addressed the rights of key populations or young people. Courtney Nemroff, the US representative, highlighted the problem in her remarks: the declaration, although an important step forward, still “lacks the ambition needed to meet the stated goals of this high-level meeting — ending inequalities and ending AIDS.”

Early in the epidemic, which quietly spread for years, and 40 years ago this month began to receive attention from healthcare workers, scientists and activists, financing appeared to be the main obstacle to protecting the health and welfare of all those affected by HIV. There were some who thought the global “mortgage” of a commitment to treat all could never be fully funded. This was never true, and COVID-19 has shown that money flows when the political will exists. The additional US$10 billion in investment that UNAIDS calls for to end the HIV epidemic by 2030 seems modest in comparison to COVID-19 investments.

What the COVID-19 response and last week’s declaration demonstrate is that the biggest obstacle to overcoming HIV and other health threats is not money but laws and policies that affect access to prevention, treatment and care for all populations. The declaration commits to reducing annual HIV infections to under 370,000 people and to ensure by 2025 that 95 percent of people at risk of HIV infection are able to obtain appropriate, person-centered and effective combination prevention. But how can this be achieved when countries continue to criminalize or restrict the autonomy and rights of those people they need to reach?

A number of organizations and activists have spoken out after the adoption of the declaration. Together these responses represent a community amendment to the declaration. Together they say ‘yes’ to the declaration and

  • Protect human rights and eliminate structural barriers that result in discrimination, gender inequality, underfunding and excluding people living with HIV and people most at risk of HIV, such as key populations, priority populations and children who may be at elevated risk of HIV.
  • Protect the sexual and reproductive health and rights of women and girls, eliminate gender-based inequalities, gender-based violence, stigma and discrimination, as well as punitive legal and policy environments.
  • Commit to global accessibility, availability and affordability of safe, effective and quality-assured medicines, including generics, vaccines, diagnostics and other health technologies to prevent, diagnose and treat HIV infection.

Even though the vote on June 8 was overwhelmingly in favor of the Political Declaration on HIV and AIDS, the problem with a split vote is that it no longer sets the standards for policy in the way that a consensus adoption does. A new study from Georgetown University found little evidence in support of the argument that criminalizing behavior of marginalized people in a pandemic results in positive outcomes for them or their national response. The Political Declaration could have defined the minimum standards for developing policies that support those most at risk of HIV. Instead, it becomes the ceiling that may never be reached by many countries, unless civil society again makes the case and governments actually adopt policies that acknowledge that there is no end to the HIV epidemic without involving, supporting and accepting everyone.

Protecting Global Gains: Connecting Ecuador’s indigenous communities to health care

The latest Protecting Global Gains, Connecting Ecuador’s indigenous communities to health care through training in native languages, describes how health workers are reaching marginalized and geographically isolated communities during the ongoing pandemic.

Thanks to an innovative virtual training program launched by Universidad Católica de Cuenca and Project HOPE—a global health and humanitarian assistance organization—community health workers in Ecuador are delivering critical messaging on COVID-19 prevention in the native languages of Kichwa and Shuar. Health workers who successfully complete the training form a health brigade responsible for educating at least 2,000 local leaders who continue the knowledge-sharing within their own communities. By using local languages to communicate the importance of mask wearing, social distancing and handwashing, healthcare workers are providing life-saving health information to some of the most rural and far-flung communities.

Ecuador’s community health workers and this inclusive outreach holds promise beyond the context of COVID-19; the health brigades can help administer standard childhood vaccines, conduct prenatal consultations, and provide treatment for common ailments, much of which has been placed on hold during the pandemic lockdowns. The program’s success highlights the importance of adaptive and client-centered services that are responsive to the unique needs of marginalized populations.

Follow Protecting Global Gains on social media at @HIVpxresearch, @theglobalfight, @Amref_Worldwide, and #ProtectingGlobalGains, and consider amplifying these stories on your own social media. Advocates who are health care professionals can also join Project HOPE’s volunteer roster to help strengthen health systems in vulnerable communities around the world. Visit www.protectingglobalgains.org to learn more about how to take action.

40 years of HIV/AIDS, and 18 months of COVID: Resources and Perspectives

It’s 18 months and counting since COVID-19 hit the world, and it’s 40 years this week since the first cases of HIV appeared in the Morbidity and Mortality Weekly Report of the CDC. Both epidemics have deeply scarred humankind, and neither can be vanquished without prevention. That message is vital to remember as the UN High Level Meeting (HLM) on AIDS begins next week—20 years since the first UN General Assembly Special Session on HIV/AIDS that led to the establishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria.

At AVAC.org we have new resources to support your advocacy and get you the latest information on the prevention pipelines for both HIV and COVID-19—and some recommended reading, too, from some friends and colleagues:

We hope you’ll scroll down for a roundup of recently updated materials. And we hope you’ll join a side meeting at the HLM, No Prevention, No End: The importance of leadership for HIV prevention—How decisions can turn an epidemic. Register to support the urgent need for leadership to reach the 2030 UN targets. And to see the larger conversation of the HLM, and AVAC’s take, on Twitter, follow #HLM2021AIDS.

The HIV Prevention Pipeline

  • AVAC’s classic infographic, The Future of ARV-Based Prevention and More, has a fresh update. It offers a look at the range of non-vaccine technology moving from pre-clinical through phase IV trials.
  • HIV Vaccine Awareness Day on May 18th brought a slew of resources for vaccine advocacy. On AVAC’s dedicated page for HVAD 2021 you will find key messages, a PowerPoint for basic vaccine science, podcasts, opinion pieces and more.
  • You won’t want to miss the June 29th webinar, What’s Your Pleasure? Expanding Your Choices on the HIV Prevention Buffet. The talk will be both a scientific update on the research pipeline—with Dr. Linda-Gail Bekker from the Desmond Tutu Health Foundation, Dazon Dixon Diallo from SisterLove, and Rob Newells from the Black AIDS Institute—and a happenin’ gathering with spoken word artist Storie Deveraux and DJ set by DJ Triple D. Register here.

Updates On COVID Vaccines

How to be #HIVvaccineaware this #HVAD2021

Today, May 18th, is HIV Vaccine Awareness Day (HVAD), and advocates are calling for policies, science and advocacy for HIV vaccines that leverage the lessons of the past year.

This HVAD, we are focused on how the COVID experience can speed the development AND delivery of vaccines for HIV, TB, malaria and other diseases. Below you’ll find a roundup of resources, from AVAC and others, providing context, key messages and other information on what the field has learned from COVID-19, the essential role of vaccines in global health, and what’s next in the search for an HIV vaccine.

Vaccines & Global Health in Perspective

  • In a commentary today in Bhekisisa, Fatima Hassan of Health Justice Initiative and AVAC’s Mitchell Warren outline Finding an HIV vaccine: Five lessons from the response to COVID-19.
  • Episode 1 of the new podcast from the International AIDS Society (IAS), HIV Unmuted takes listeners to the global HIV change-makers who have shaped the response and asks what must happen now to end the AIDS epidemic. This debut episode features the NIH’s Anthony Fauci, AVAC’s Maureen Luba, Udom Likhitwonnawut from Thailand’s National Community Advisory Board, and others.
  • In their piece, How HIV Vaccine Advocacy Can Leverage Lessons from COVID-19, USAID’s Ashley Lima and Margaret McCluskey draw on the experiences and perspective of CASPR partners and their agenda for vaccine advocacy in the midst of COVID.

AVAC’s HVAD Package
Check out AVAC’s key messages for this HVAD. Designed for easy communication, this resource outlines the six ways that the COVID experience can shape HIV vaccine advocacy moving forward. For social media, we hope our sample tiles and tweets will inspire action to keep audiences #HIVvaccineaware this #HVAD2021. Download tiles 1, 2, 3, 4, 5, 6. Get the basics with AVAC’s annually updated powerpoint tutorial on HIV vaccines; current and planned vaccine research with this table of clinical trials; and our infographics gallery allows you to search by prevention intervention. All of these resources and more are up at www.avac.org/hvad.

IAVI’s HVAD Resources
We encourage you to explore IAVI’s #HVAD2021 toolkit for the perspectives of scientists and community liaison teams, videos on the science and development of vaccines, and tiles and tweets supporting their HVAD campaign at #EyesOnTheTarget and more.

Updates from the Field

  • Earlier today, WACI Health and AfNHI hosted a webinar exploring the remarkable advances in HIV vaccine research and the promising concepts being studied today with Ntando Yola, of APHA-South Africa and the Desmond Tutu Health Foundation, and Nyaradzo Mgodi, clinical pathologist from the University of Zimbabwe. Look for a recording of the webinar here, along with recordings of two additional webinars: one co-hosted by IAVI and KANCO featuring leading researchers and advocates in East Africa and one co-hosted by IAVI and SANAC featuring leaders in South Africa.
  • On May 13th, AVAC hosted a webinar HIV Vaccines in the Midst of COVID. In this recording you’ll hear researchers and advocates discussing new vaccine technologies, delivery challenges, community engagement, and confidence in both vaccines and vaccine research.
  • In the latest episode of AVAC’s Px Pulse podcast, Dive into the AMP Trials, we unpack the results of the recent Antibody-Mediated Prevention (AMP) studies, which will inform the fields of antibodies-for-prevention, and HIV vaccine research.

We can make #HVAD2021 the turning point, when the full potential of vaccines becomes undeniable, and the world renews its commitment to the search for vaccines for HIV, TB and other diseases that continue to threaten so many people’s health and well-being.

On this HIV Vaccine Awareness Day, leveraging the lessons of COVID to advance an HIV vaccine

This HIV Vaccine Awareness Day—observed each year on May 18—takes place in a new era of vaccine science. Accelerated by the knowledge, technologies, networks and community engagement models developed for HIV, the search for COVID-19 vaccines produced extraordinary results in record time. COVID demonstrated that a global sense of urgency to end a pandemic can produce ample research money overnight, help pharmaceutical companies, academic institutions, and nonprofits overcome previously insurmountable barriers to collaboration, and shrink vaccine development and testing timelines from decades to months. And yet, the results of those innovations are not translating quickly or equitably enough to end this pandemic. Advances in scientific R&D can’t have impact without equally robust investment in and commitment to delivery.

AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID”. We are focused on how the COVID experience can speed the development AND delivery of vaccines for HIV, TB, malaria and other diseases. Visit our dedicated HVAD 2021 page for resources to help make sense of this unique moment in vaccine history, and to build a global vaccine advocacy agenda for the future. There you’ll find:

The 2021 HVAD toolkit:

The page also has links to:

  • A recording of yesterday’s webinar, HIV Vaccines in the Midst of COVID, featuring HIV vaccine researchers and advocates Barney Graham (NIH Vaccine Research Center), Definate Nhamo (PZAT), Linda-Gail Bekker (Desmond Tutu Health Foundation), Matthew Rose (Health GAP) and Pontiano Kaleebu (MRC/UVRI & LSHTM Uganda Research Unit), discussing new vaccine technologies, delivery challenges, community engagement, and confidence in both vaccines and vaccine research.
  • A new episode of our Px Pulse podcast, Dive into the AMP Trials, which helps explain the results of the recent Antibody-Mediated Prevention (AMP) study and what it could mean for HIV vaccines.
  • Clinical Trials Update – A table of past, current and planned vaccine trials.
  • Infographics gallery – Search by intervention—antibody-mediated prevention or HIV vaccine—for all the latest infographics.

The opportunities and challenges brought to light by COVID make this an HIV Vaccine Awareness Day like no other. This #HVAD2021, we must all become #HIVvaccineaware and ensure new vaccines get developed and delivered!

New Resources on AVAC.org and PrEPWatch

In this round-up of new AVAC resources you’ll find a wide range of new resources:

Understanding the Latest in HIV Prevention Research

HIV Vaccine Awareness Day is just around the corner—May 18th! In preparation, AVAC hosted a webinar, HIV Vaccines in the Midst of COVID, on Thursday, May 13.

An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP: In 2020, two large-scale efficacy trials, HPTN 083 & 084, found that a long-acting injectable form of cabotegravir as PrEP provided high levels of protection among people at risk of HIV. That’s truly exciting. There’s also a lot to learn and understand about next steps. What do the trial results explain, what still needs to be explored, and what do advocates think needs to happen next? Check out our primer for what’s known and what’s next for this emerging biomedical HIV prevention strategy.

A webinar: Long-Acting Injectable Cabotegravir for PrEP – Understanding the results and key areas for advocacy: AVAC’s May 3rd webinar on CAB-LA featured the researchers who led the studies on long-acting injectable PrEP, and advocates who are defining key issues for the introduction of CAB-LA.

Dive into the AMP Trials: In this episode of Px Pulse, AVACers Jeanne Baron and Daisy Ouya talk to leading bNAb researcher, IAVI’s Devin Sok; veteran HIV research advocate Mark Hubbard who served on AMP’s protocol team; and a senior member of the HVTN’s community engagement team, a chief explainer of the AMP trails, Gail Broder. Together they explore why these findings point to the need for combination antibodies, the need for a better understanding of the types of HIV that are circulating in a community, the complicated implications of a key lab test, the TZM-bl assay, and more.

Developments in the HIV Prevention Pipeline: PrEP, vaccines and more: Created by AVAC, EATG, PrEP in Europe, and PrEPster, this slide deck and recorded webinar offers community educators and advocates a concise summary of existing and future PrEP products, and a community-level perspective on strategic advocacy for PrEP access and uptake.

Watchdogging PEPFAR

PEPFAR Watch is a new online resource from a collaboration working to hold PEPFAR accountable to communities. The website features reports, news, and resources to support community-led monitoring, a core initiative for accountability in PEPFAR programs. You can also sign up to become members and gain access to webinars, PEPFAR quarterly data and more. The collaboration includes Health GAP, AVAC, TAG, the O’Neill Institute, MPact, the PLUS Coalition, amfAR, and CHANGE. It should be a one stop shop for all the information you need to monitor and influence PEPFAR Country Operational Plans. Find other supportive resources on AVAC’s page: Advocate for Access to High-Impact Prevention.

A Spotlight on Equity and Ethics

Make Your Voice Heard: Towards advancing racial equity & diversity in biomedical research: In response to a call from the NIH for proposals to advance racial equity, diversity, and inclusion within all facets of the biomedical research workforce, and expand research to eliminate or lessen health disparities and inequities, AVAC’s John Meade authored a blog on the major recommendations offered to the NIH from a coalition of 25 HIV research advocate organization.

How can research ethics committees help to strengthen stakeholder engagement in health research in South Africa? An evaluation of REC documents: This article, co-authored by our CASPR partners at South Africa’s HIV AIDS Vaccines Ethics Group (HAVEG) and AVAC’s Jess Salzwedel, and published in the South African Journal of Bioethics and Law, recommends research ethics committees (RECs) step up the focus on stakeholder engagement. Researchers working with REC’s should plan for robust stakeholder engagement and REC documentation should be harmonized to reflect this priority.

Advocacy for Vaccine Access

Breaking the Bottlenecks to COVID-19 Vaccine Access: Ensuring global access to COVID vaccines—and any health commodity—requires a multi-pronged effort to get the right policies in place. This new infographic identifies the multiple factors that contribute to bottlenecks in the global supply of #COVID19 vaccines and how to address them.

We hope these resources, which cut across issues facing the field, will empower your advocacy where change is both crucial and possible.

New Episode of Px Pulse! Dive into the AMP Trials

Findings from two trials on antibody-mediated prevention, the AMP Trials, have been generating discussion since the beginning of the year. The results are complex, and the implications for HIV prevention research are unfolding. The overall efficacy finding from these two Phase IIb studies was not protective. But when the broadly neutralizing antibody (bNAb) known as VRC01 was fighting strains of HIV that were highly sensitive to it, the antibody did provide partial protection. So what does that mean for the field, and what other questions have been raised by these pioneering trials?

In this episode of Px Pulse, AVACers Jeanne Baron and Daisy Ouya talk to leading bNAb researcher, IAVI’s Devin Sok; a veteran HIV research advocate Mark Hubbard who served on AMP’s protocol team; and a senior member of the HVTN’s community engagement team, a chief explainer of the AMP trials, Gail Broder. Together, we explore why these findings point to the need for combination antibodies, the need for a better understanding of the types of HIV that are circulating in a community, the complicated implications of a key lab test and more.

For more resources on these trials and antibody research for HIV prevention generally, AVAC has you covered. See AVAC’s dedicated page on the AMP trials, stay tuned for our forthcoming publication on “understanding the AMP results”, and for a broader context go to our page on antibody related research with access to our updated graphics on individual bNAbs and combinations.

Also, be sure to check out IAVI’s special report out today, The Future of antibody-based HIV Prevention, which analyzes the results and deepens the discussion with insights from experts across the field.

For the full podcast episode, highlights and more resources, visit avac.org/px-pulse. And subscribe on Apple Podcasts, Spotify or wherever you get your podcasts!

May 13 Webinar! HIV Vaccines in the Midst of COVID

HIV Vaccine Awareness Day is just around the corner—May 18th! In preparation, AVAC hosted a webinar, HIV Vaccines in the Midst of COVID, on Thursday, May 13.

Expert researchers and advocates discussed major issues and advances in HIV vaccine R&D and the impacts of COVID-19 on vaccine research and delivery. The conversation to explored the lessons learned to date and how they serve as a warning, a model, and a body of evidence on the need for accelerated vaccine development and comprehensive strategies for equitable global access.

The moderated panel discussion included Barney Graham of the NIH Vaccine Research Center, who helped develop the mRNA vaccine technology; Pontiano Kaleebu of the MRC/UVRI & LSHTM Uganda Research Unit who helps lead the PrEPVacc trial; Linda-Gail Bekker of the Desmond Tutu Health Foundation who is involved in cutting-edge HIV vaccine research and COVID vaccine delivery; and Matthew Rose of Health GAP and Definate Nhamo of PZAT who deal with the wide range of issues of confidence in vaccine research AND delivery.

We hope you’ll enjoy this rich conversation and prepare to make the most of your advocacy around HIV Vaccine Awareness Day on May 18. Click here for recording and slides.

AVAC will be offering additional tools in the days to come, including infographics, key messages, a social media toolkit and more. These resources will help you make the case that the fastest, but still-faltering vaccine effort in history has demonstrated both what can be done and what must be done better in the global response to pandemics. Keep an eye on this space for the latest!

Long-Acting Injectable Cabotegravir for PrEP: Understanding Results of HPTN 083 & 084 and key areas for advocacy

Join AVAC and partners for webinar on May 3 webinar, 10-11:30am EDT where you can engage with researchers who led the studies about this injectable PrEP strategy and advocates who are leading essential advocacy efforts around the introduction of CAB-LA. On the call, lead trial investigators Sinead Delany-Moretlwe from HPTN 084 and Raphy Landovitz from HPTN 083 will provide updates, and we’ll be joined by AVAC’s Emily Bass, Chiluyfa Kasanda from TALC in Zambia, Richard Lusimbo from Pan Africa ILGA, and Sibongile Maseko who is an independent consultant and women’s health advocate based in Eswatini. Register here.

Moving Ahead with Long-Acting PrEP: Webinar and updated resource on CAB-LA research and advocacy

Long-acting injectable cabotegravir (CAB-LA) for PrEP is causing buzz and raising opportunities and questions for prevention advocates. Whether you’ve got questions or want to know what the buzz is about, AVAC has you covered.

We’ve updated our comprehensive primer on CAB-LA: Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP: Understanding the Initial Results of HPTN 083 and HPTN 084, and held a May 3 webinar, 10-11:30am EDT where you can listen to the researchers who led the studies about this injectable PrEP strategy and advocates who are leading essential advocacy efforts around the introduction of CAB-LA.

On the call, lead trial investigators Sinead Delany-Moretlwe from HPTN 084 and Raphy Landovitz from HPTN 083 provided updates, and we were joined by AVAC’s Emily Bass, Chiluyfa Kasanda from TALC in Zambia, Richard Lusimbo from Pan Africa ILGA, and Sibongile Maseko who is an independent consultant and women’s health advocate based in Eswatini.

Watch the recording and find the slides here.

As our new primer describes, CAB-LA injections every eight weeks provided high levels of protection against HIV in cisgender women, cisgender men who have sex with men and transgender women who have sex with men. That’s truly exciting. There’s also a lot to learn and understand about next steps. A small number of people who received on-time injections and went on to acquire HIV did not test “HIV-positive” on standard antibody-based HIV tests. An even smaller number acquired resistance to integrase inhibitors—the class that includes cabotegravir and dolutegravir. In addition to these crucial issues, it’s also important to focus on questions of access. For those who want an injectable PrEP strategy, CAB-LA needs to be accessible and affordable.

What do the trial results explain, what still needs to be explored, and what do advocates think needs to happen next? Check out the updated resource and register the webinar to engage with it all!